These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27284260)

  • 1. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey.
    Ponzetti C; Canciani M; Farina M; Era S; Walzer S
    Clinicoecon Outcomes Res; 2016; 8():227-33. PubMed ID: 27284260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erratum: Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum].
    Clinicoecon Outcomes Res; 2017; 9():75. PubMed ID: 28174493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach.
    Ponzetti C; Canciani M; Farina M; Era S; Walzer S
    Clinicoecon Outcomes Res; 2016; 8():353-9. PubMed ID: 27536148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
    Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
    Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.
    McCloskey C; Ortega MT; Nair S; Garcia MJ; Manevy F
    Pharmacoecon Open; 2023 Jan; 7(1):3-36. PubMed ID: 35996066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.
    Jang M; Simoens S; Kwon T
    BioDrugs; 2021 Jan; 35(1):89-101. PubMed ID: 33368051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
    Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
    Harvey MJ; Zhong Y; Morris E; Beverage JN; Epstein RS; Chawla AJ
    PLoS One; 2022; 17(1):e0261336. PubMed ID: 35073335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
    O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
    Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
    Rule S; Collins GP; Samanta K
    J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study.
    Abad-Sazatornil MR; Arenaza A; Bayo J; García Mata J; Guinea De Castro JM; León J; Letellez J; Reguero V; Martínez Chamorro C; Salar A
    BMC Health Serv Res; 2021 Apr; 21(1):320. PubMed ID: 33832464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma.
    Fargier E; Ranchon F; Huot L; Guerre P; Safar V; Dony A; Hequet N; Bachy E; Savouroux S; Fronteau C; Tomaré P; Tournamille JF; Schwiertz V; Vantard N; Le Gouill S; Gyan E; Salles G; Rioufol C
    Ann Hematol; 2018 Jan; 97(1):123-131. PubMed ID: 28993857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion.
    Mihajlović J; Bax P; van Breugel E; Blommestein HM; Hoogendoorn M; Hospes W; Postma MJ
    Clin Ther; 2017 Jun; 39(6):1221-1232.e4. PubMed ID: 28579210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
    Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
    PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimisation analysis of intravenous versus subcutaneous trastuzumab regimen for breast cancer management in Hong Kong.
    Lee VWY; Cheng FWT
    Hong Kong Med J; 2023 Feb; 29(1):16-21. PubMed ID: 36731884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
    Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
    Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients.
    Farolfi A; Silimbani P; Gallegati D; Petracci E; Schirone A; Altini M; Masini C
    Oncotarget; 2017 Oct; 8(46):81343-81349. PubMed ID: 29113393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.
    North RT; Harvey VJ; Cox LC; Ryan SN
    Clinicoecon Outcomes Res; 2015; 7():423-30. PubMed ID: 26251623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)].
    Favier M; Le Goc-Sager F; Vincent-Cantini I; Launay V; Giroux EA; Lièvremont K; Bonnet I; Barbe C; Duval E; Loric N; Delbaldo C
    Bull Cancer; 2018 Oct; 105(10):862-872. PubMed ID: 30244982
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.